Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

David A. Hyman, MD, JD, on Inclusive Shared Savings

Welcome and Introduction to Vi3C

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Jun

Today In Oncology

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

David A. Hyman, MD, JD, on Inclusive Shared Savings

Welcome and Introduction to Vi3C

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

PROTEUS Trial Suggests Perioperative Apalutamide May Improve Outcomes in High-Risk Localized Prostate Cancer

Adjuvant Selpercatinib Improves Event-Free Survival in RET-Positive Early-Stage NSCLC

Implanted Cesium-131 Tiles Improve Local Control and Survival in Patients With Resected Brain Metastases

Many Patients With Limited Sentinel Node–Positive Breast Cancer Can Safely Avoid Axillary Dissection, Study Shows

Overall Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Squamous NSCLC